EQS News: Immunic to host Multiple Sclerosis R&D Day in September and participate in scientific and investor conferences Page 1

NEW YORK, August 28, 2024 –

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day in September and participate in the following scientific and investor conferences:

• September 10: Immunic’s MS R&D Day. Immunic’s leadership, including Daniel Vitt, Ph.D., Chief Executive Officer; Jason Tardio, MBA, Chief Operating Officer and President; Andreas Muehler, MD, MBA, Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, will be joined by two renowned MS industry experts to discuss the MS landscape, as well as Immunic’s orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), and its potential to become the treatment of choice for both relapsing and progressive MS patients.
  • Date: Tuesday, September 10, 2024
  • Time: 10:30am – 12:30pm ET, followed by a networking lunch
  • Location: One Five One, 151 West 42nd Street, New York, NY 10036
  • Featured Experts:
    • Francesca Montarolo, Ph.D., Neuroscience Institute Cavalieri Ottolenghi (NICO) and University Hospital San Luigi Gonzaga of Orbassano, Turin, Italy
    • Amit Bar-Or, MD, FRCPC, Melissa and Paul Anderson Distinguished Chair, Director, Center for Neuroinflammation and Experimental Therapeutics, Chief of the Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania
  • RegisterYou can register by sending an email to: [email protected].

• September 18-20: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Members of Immunic’s management, medical, clinical and preclinical teams will attend the conference in Copenhagen, Denmark. Data on vidofludimus calcium will be presented in an oral presentation and three ePosters. In addition, the team will be available at booth #60 throughout the event. All poster presentations can be accessed in the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.
• Oral poster presentation:
  • Title: Serum neurofilament changes in progressive MS: investigating the impact of vidofludimus calcium on age and disability in the CALLIPER study interim analysis
  • Presenting author: Robert J. Fox, Staff Neurologist, Mellon Center for Multiple Sclerosis, Vice Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
  • Poster number: P753
  • Session title: Poster session 2
  • Session date: Thursday, September 19, 2024
  • Session time: 16:45 – 18:45 CEST
• ePosters:
  • Title: Investigating the potential of Vidofludimus Calcium to reduce fatigue in multiple sclerosis by preventing reactivation of the Epstein-Barr virus
  • ePoster number: P1119
  • Title: Vidofludimus Calcium activity on NURR1 in preclinical models: a potential neuroprotective role in multiple sclerosis
  • ePoster number: P1410
  • Title: Vidofludimus Calcium Shows T Helper Cell Modulatory Effects in Experimental Murine Autoimmune Encephalomyelitis: One Possible Mode of Action for the Treatment of MS
  • ePoster number: P1390

• September 2-4: DMDG-50^and Public meeting 2024. Juliano R. Fonseca, Ph.D., head of preclinical development at Immunic, will present data from Immunic’s open-label mass balance and pharmacokinetic phase 1 study of vidofludimus calcium in a poster presentation at the meeting in York, United Kingdom.
  • Title: Mass balance and ADME properties of (¹⁴C)-IMU-838 After oral administration to healthy male subjects
  • The presentation and specific poster number and session details can be found in the ‘Events and Presentations’ section of the Immunic website: https://ir.imux.com/events-and-presentations, as soon as they become available.

• September 5-7: 20^and International Celiac Disease Symposium ICDS. Martina Wirth, Senior Manager Translational Pharmacology at Immunic, will present data from Immunic’s Phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a groundbreaking poster presentation at this symposium in Sheffield, United Kingdom.
  • Title: First-in-human trial of IMU-856, an orally available epigenetic modulator of barrier function and regeneration for the treatment of celiac disease
  • The presentation and specific poster number and session details can be found in the ‘Events and Presentations’ section of the Immunic website: https://ir.imux.com/events-and-presentations, as soon as they become available.
• September 17-19: Cantor Fitzgerald Global Healthcare Conference 2024. Dr. Vitt will participate in a fireside chat at the conference in New York on Wednesday, September 18, 2024 at 3:05 p.m. ET. A webcast of the presentation will be available in the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations. An archived replay will be available on the company’s website for a period of 90 days following the conference.

About Immunic, Inc.

Diskutieren Sie über die entaltenen Werte